Skip to Main Content (Press Enter)

Logo UNIMORE
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNIMORE

|

UNI-FIND

unimore.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

Prognostic factors in node positive primary breast cancer patients treated with adjuvant CMF.

Articolo
Data di Pubblicazione:
1992
Citazione:
Prognostic factors in node positive primary breast cancer patients treated with adjuvant CMF / E., C., P., P., D., A., G. F., B., M., V., E., B., I., B., M. R., S., Conte, P., R., R.. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 12:(1992), pp. 1555-1558.
Abstract:
The influence of various patient and disease-related parameters on survival (S) and disease-free survival (DFS) in 217 node positive primary breast cancer patients treated with surgery followed by adjuvant i.v. cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) was evaluated by univariate and multivariate analyses. Five year actuarial S and DFS were 73.3\% and 54.8\%, respectively. Univariate analysis revealed that patient age, number of involved axillary nodes and ER status had a significant impact on both S and DFS. PgR positive tumors had improved DFS but no S difference was observed. Menopausal status predicted S but not DFS. Primary tumor size and CMF-induced amenorrhea did not predict disease outcome. Multivariate analysis demonstrated that only degree of nodal involvement and PgR status had independent significant impact on prognosis. Both S and DFS are significantly influenced by the number of involved nodes, whereas improved DFS but not S was evident in patients with PgR positive tumors.
Tipologia CRIS:
Articolo su rivista
Keywords:
Adult, Antineoplastic Combined Chemotherapy Protocols; therapeutic use, Breast Neoplasms; drug therapy/pathology/surgery, Cisplatin; administration /&/ dosage, Female, Fluorouracil; administration /&/ dosage, Follow-Up Studies, Humans, Lymphatic Metastasis, Methotrexate; administration /&/ dosage, Middle Aged, Prognosis, Receptors; Estrogen; analysis, Receptors; Progesterone; analysis, Survival Analysis, Time Factors
Elenco autori:
E., Campora; P., Pronzato; D., Amoroso; G. F., Bertelli; M., Venturini; E., Baldini; I., Brunetti; M. R., Sertoli; Conte, Pierfranco; R., Rosso
Link alla scheda completa:
https://iris.unimore.it/handle/11380/739562
Pubblicato in:
ANTICANCER RESEARCH
Journal
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.6.1.0